ClinicalTrials.gg
CompletedNCT07850778ONS COLON CAUpdated Sep 30, 2026

ONS USE IN COLON CANCER

An observational study in Oral Nutritional Supplementation and Colon Cancer, sponsored by Osmaniye Korkut Ata University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Osmaniye Korkut Ata University · Observational

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
209
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Colonic Neoplasms with a site in Turkey — 7 open to participants now, 11 under way, 2 of them phase 3. Colonic Neoplasms · Turkey.

Enrollment
6th of 13
209 · median 140
Started
2021
with 5 others
Observational
13 of 29
2 open now
Registered
28th of 29
by date

Among the 29 studies in Colonic Neoplasms with a site in Turkey, this one is the 6th largest by enrollment of the 13 observational ones that give a count, is one of 6 that started in 2021, is one of 13 observational ones, and was the 28th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

7 of the 29 studies in Colonic Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colonic Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This retrospective observational cohort study examined oral nutritional supplement (ONS) use and associated factors in patients receiving adjuvant mFOLFOX6 chemotherapy after curative surgery for stage III colon cancer. Medical and routine nutrition follow-up records from Osmaniye Training and Research Hospital between January 2021 and January 2026 were reviewed. The study included 362 patients prescribed ONS. The main outcomes were ONS non-initiation or early discontinuation and failure to meet a study-defined consumption criterion among ONS users. Demographic, clinical, nutritional, and psychosocial factors associated with these outcomes were evaluated.

Read the detailed description

Oral nutritional supplements (ONS) are prescribed to support nutritional intake when patients cannot meet their requirements through regular foods. However, prescribed supplements may not be initiated or consumed in the recommended amounts and duration. This single-center retrospective cohort study evaluated ONS consumption patterns and associated factors in adults with stage III colon adenocarcinoma receiving adjuvant mFOLFOX6 chemotherapy after curative surgery.

Data were obtained from electronic medical records, operative and pathology reports, oncology records, and routine Nutrition Outpatient Clinic forms for patients followed between January 2021 and January 2026. Eligible patients were aged 18 years or older, had been prescribed ONS during adjuvant chemotherapy, and had at least three months of clinical and nutritional follow-up with complete analytical data. No research-specific intervention or additional patient contact occurred.

Patients who never initiated ONS or used them for fewer than 7 days were classified as ONS non-users/early discontinuers. Patients who used ONS for at least 7 days were classified as ONS users. Among users, consumption of at least 75% of the recommended daily amount for at least 4 weeks was defined as meeting the study-specific consumption criterion. Consumption was assessed using patient-reported intake documented in routine follow-up records over approximately three months after prescription. Objective container counts or electronic consumption monitoring were not performed.

Recorded variables included demographic characteristics, living arrangements, comorbidities, surgical characteristics, postoperative complications, body mass index, Prognostic Nutritional Index, Nutritional Risk Screening 2002 scores, and Beck Depression Inventory scores. Reasons for ONS non-use, symptoms reported during ONS use, and attendance at dietitian follow-up visits were also evaluated.

Exploratory logistic regression analyses examined factors associated with non-initiation/early discontinuation among all eligible patients and failure to meet the consumption criterion among ONS users. Associations were interpreted as observational and did not establish causality.

03

Conditions studied

  • Oral Nutritional Supplementation
  • Colon Cancer

Browse trials for

Keywords

  • colon cancer
  • oral nutritional supplements
  • adherence to ONS
  • adjuvant chemotherapy
  • dietitian follow-up
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with histopathologically confirmed stage III colon adenocarcinoma who underwent curative surgery, received adjuvant mFOLFOX6 chemotherapy, and were prescribed ONS at Osmaniye Training and Research Hospital between January 2021 and January 2026.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Histopathologically confirmed stage III colon adenocarcinoma according to the eighth edition of the AJCC TNM classification.
  • Previous curative surgery for colon cancer.
  • Receipt of mFOLFOX6 chemotherapy.
  • Prescription of oral nutritional supplements (ONS) during adjuvant chemotherapy.
  • At least three months of clinical and Nutrition Outpatient Clinic follow-up.
  • Complete medical and nutritional records for the variables required for analys

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or postpartum status.
  • Receipt of or palliative treatment.
  • Receipt of chemotherapy regimens other than mFOLFOX6.
  • Active second .
  • Dementia or a history of cerebrovascular disease.
  • Dysphagia, previous upper gastrointestinal surgery, or food allergy precluding safe ONS use.
  • Additional major surgery performed during colectomy.
  • Preoperative ONS use.
  • ONS usage that could not be assessed from available records.
  • Missing follow-up information or analytical data.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
209 participants (actual)
Patient registry
No

Groups and cohorts

  • ONS Non-Users/Early Discontinuers

    Patients with stage III colon cancer who were prescribed oral nutritional supplements (ONS) during adjuvant mFOLFOX6 chemotherapy after curative surgery but never initiated ONS or used them for fewer than 7 days, based on patient-reported consumption documented in routine nutrition follow-up records.

  • ONS Users

    Patients with stage III colon cancer who were prescribed oral nutritional supplements (ONS) during adjuvant mFOLFOX6 chemotherapy after curative surgery and used them for at least 7 days, based on patient-reported consumption documented in routine nutrition follow-up records. These patients were further classified according to whether they consumed at least 75% of the recommended daily amount for at least 4 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Oral Nutritional Supplement Non-Initiation or Early

    Percentage of patients prescribed oral nutritional supplements (ONS) who never initiated use or used ONS for fewer than 7 days. The denominator includes all eligible patients prescribed ONS. Usage status was determined retrospectively from patient-reported consumption documented in routine nutrition follow-up records.

    Time frame: From ONS prescription to approximately 3 months after prescription.

  2. Percentage of Patients With Oral Nutritional Supplement Non-Initiation or Early Discontinuation

    Percentage of patients prescribed oral nutritional supplements (ONS) who never initiated use or used ONS for fewer than 7 days. The denominator includes all eligible patients prescribed ONS. Usage status was determined retrospectively from patient-reported consumption documented in routine nutrition follow-up records.

    Time frame: From ONS prescription to approximately 3 months after prescription.

  3. Percentage of ONS Users Not Meeting the Study-Defined Consumption Criterion

    Percentage of patients using oral nutritional supplements (ONS) for at least 7 days who did not meet the study-defined consumption criterion of consuming at least 75% of the recommended daily amount for at least 4 weeks. Failure to meet either threshold was classified as not meeting the criterion. The denominator includes patients who used ONS for at least 7 days. Consumption was assessed retrospectively using patient-reported intake documented in routine nutrition follow-up records.

    Time frame: From ONS prescription to approximately 3 months after prescription.

07

Study locations

1 site
  • osmaniye korkut ata üniversitesi KARACAOĞLAN YERLEŞKESİ D blok sağlık bilimleri fakültesi 1. kat oda no:101
    Merkez, Osmaniye 80000, Turkey (Türkiye)
08

References and documents

Publications

  • Pi JF, Zhou J, Lu LL, Li L, Mao CR, Jiang L. A study on the effect of nutrition education based on the goal attainment theory on oral nutritional supplementation after colorectal cancer surgery. Support Care Cancer. 2023 Jul 6;31(7):444. doi: 10.1007/s00520-023-07905-1. PubMed 37410217 ↗
  • Lidoriki I, Frountzas M, Karanikki E, Katsarlinou E, Tsikrikou I, Toutouzas KG, Schizas D. Adherence to Oral Nutrition Supplementation in Gastrointestinal Cancer Patients: A Systematic Review of the Literature. Nutr Cancer. 2024;76(1):31-41. doi: 10.1080/01635581.2023.2277519. Epub 2023 Dec 27. PubMed 37946396 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared. This retrospective study used patient medical and nutritional follow-up records containing sensitive health information. Only aggregate study results will be disseminated to protect participant privacy and confidentiality.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jan 2026, 60 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Jan 1, 2021
Primary completionActual
Jan 1, 2026
CompletionActual
Jan 1, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850778
Lead sponsor
Osmaniye Korkut Ata University
Responsible party
AYBALA TAZEOGLU (Assistant Professor, Osmaniye Korkut Ata University) — Principal investigator
First posted
Sep 30, 2026
Start date
Jan 1, 2021
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion